The CART Take-off guidance includes a section on Public Health Risk Mitigation Measures, in addition to four operational modules relating to:
The impact of the coronavirus disease (COVID-19) pandemic on global air transport is without precedent. Airports have seen a -28.4 per cent decline in global passenger traffic volumes for the first quarter of 2020, equivalent to a reduction of 612 million passengers in absolute terms. These volumes (domestic and international traffic) are expected to decrease by -50.4 per cent for 2020 as a whole as compared to 2019 figures.
ICAO estimates that by the end of 2020, the COVID-19 impact on scheduled international passenger traffic could reach reductions of up to 71 per cent of seat capacity and up to 1.5 billion passengers globally. Airlines and airports face a potential loss of revenue of up to USD 314 billion3 and USD 100 billion respectively, for 2020.
This document provides a framework for addressing the impact of the current COVID-19 pandemic on the global aviation transportation system. The appendix to this document includes mitigations needed to reduce public health risk to air passengers and aviation workers while strengthening confidence among the travelling public, the global supply chain including, and governments. This will assist in accelerating demand for essential and non-essential air travel impacted by COVID-19.
With help and guidance from the civil aviation stakeholder community, ICAO recommends a phased approach to enable the safe return to high-volume domestic and international air travel for passengers and cargo. The approach introduces a core set of measures to form a baseline aviation health safety protocol to protect air passengers and aviation workers from COVID-19. These measures will enable the growth of global aviation as it recovers from the current pandemic.
It is, however, important to recognize that each stage of that recovery will need a recalibration of these measures in support of the common objective, which is to safely enable air travel, to incorporate new public health measures into the aviation system, as well as to support economic recovery and growth. Our work must recognize the need to reduce public health risk while being sensitive to what is operationally feasible for airlines, airports and other aviation interests. This is essential to facilitate the recovery during each of the forthcoming stages.
In the aftermath of the COVID-19 outbreak, States, including government regulators,
airports, airlines, and aircraft manufacturers among other stakeholders of the aviation ecosystem developed, in coordination with public health authorities, a set of measures aimed at reducing health risks to air travellers, aviation workers, and the general public.
These measures, applicable to States, airport operators, airlines, and others in the air transport industry, are designed to enable a consistent and predictable travel experience. They will also contribute to the efficient, safe, secure, and sustainable transport by air of an increasing number of passengers and cargo and will minimise the risk of COVID-19 transmission between and among these groups and the general public. The implementation of these measures will facilitate and strengthen the global recovery from the COVID-19 pandemic.
In developing the measures contained in the appendix, the drafters were guided by the
Based on these guiding considerations, the drafters further agreed that these measures
commensurate to the risk level and shall not compromise aviation safety and aviation security;
able to capitalize on the sector's longstanding experience and apply the same principles used for safety and security risk management. This includes monitoring compliance, reviewing the effectiveness of measures at regular intervals, and adapting measures to changing needs as well as improved methods and technologies;
Resumption of higher volumes of passenger air travel will be dependent on a number of factors, including foremost public health agency guidelines (driven by travel risk levels), governmental travel restrictions and requirements, passenger confidence, and air carrier and airport operational capacity.
A risk-based approach will enable transitioning between stages of restarting operations and adjusting the mitigation measures based on risk, while recognizing that reverting to previous stages may be necessary. The goal is to maximize consistency and to develop criteria for data reporting and the monitoring processes in support of evaluation and progression to the next stage(s). It is currently not feasible to provide any specificity of timing between these stages. At the time this document was published, most of commercial passenger aviation was in Stage 0 or Stage 1.
A situation with travel restrictions and only minimal movement of passengers between
major domestic and international airports.
Initial increase of passenger travel. This initial stage will coincide with relatively low
passenger volumes, allowing airlines and airports to introduce aviation public health practices appropriate to the volume. There will be significant challenges as each stakeholder community adapts to both increased demand and the new operational challenges associated with risk mitigation. Health measures for travel required at airports will need to, at a minimum match those from other local modes of transport and infrastructure.
As health authorities review the applicability of measures based on recognized medical criteria, passenger volumes will continue to increase. Several measures that were required in Stages 0 and 1 may be lifted. Health measures for travel required at airports will need to match those from other local modes of transport and infrastructure.
May occur when the virus outbreak has been sufficiently contained in a critical mass of major destinations worldwide as determined by health authorities. The reduction of national health alert levels and associated loosening of travel restrictions will be key triggers. Risk mitigation measures will continue to be reduced, modified, or will be stopped in this stage. There may not be effective pharmaceutical interventions (e.g. therapies or vaccines) commonly available during Stage 3, but contact tracing and testing should be readily available. Until specific and effective pharmaceutical interventions are available, States may need to continue to loosen or reinstate public health and social measures throughout the pandemic.
Begins when specific and effective pharmaceutical interventions readily available in most countries. There may be a set of residual measures/mitigations that could be retained, although these too should undergo a periodic review process.
Note: There are no hard boundaries in these stages and the transition between them can be in either direction.